How Does a Poor Huvos Grade Affect Osteosarcoma Prognosis?

When chemotherapy is given before surgery (often called neoadjuvant chemotherapy) to treat osteosarcoma, doctors evaluate how well the tumor responded by looking at it under a microscope after it is removed. Huvos grading is a system used to measure this histologic response based on the estimated percentage of the tumor that is dead—a process known as tumor necrosis ^[1]. If your child’s pathology report shows less than 90% tumor necrosis (classified as Huvos Grade I or II), this is considered a “poor” histologic response ^[2].

While this means the tumor showed less response to the initial chemotherapy, it does not mean the treatment completely failed, nor does it guarantee the cancer will return ^[3]. Doctors will use this information alongside other clinical factors to guide your child’s postoperative care and long-term surveillance (planned follow-up visits and scans).

The Huvos Grading System Explained

Pathologists evaluate representative sections of the surgically removed tumor and assign a Huvos grade based on their microscope-based estimate of how much cancer was destroyed by the preoperative chemotherapy ^[1]. Because grading is an estimate, it is not a direct count of every single cell in the body. The grades are generally defined as follows:

• Grade I: Little to no response to chemotherapy, meaning most of the tumor cells are still alive (viable) ^[2].
• Grade II: A partial response, but with less than 90% of the tumor destroyed ^[2].
• Grade III: A good response, with more than 90% but less than 100% of the tumor cells dead (some viable cells remain) ^[2].
• Grade IV: 100% necrosis, meaning no viable tumor cells are identified in the examined specimen ^[4][2]. (Note: This means no living cancer was found in the removed tumor, but it does not guarantee that microscopic disease is absent elsewhere in the body.)

In clinical practice, Grades I and II (less than 90% necrosis) are grouped together as a poor histologic response, while Grades III and IV (90% to 100% necrosis) are considered a good histologic response ^[2][5]. Terminology and exact percentage boundaries can sometimes vary slightly between laboratories, so it is always best to ask your oncologist exactly how your child’s report was classified.

What Does a Poor Response Mean for Prognosis?

Hearing that your child had a “poor response” to chemotherapy is incredibly frightening. In medical research, population-level data shows that less than 90% necrosis is associated with a higher average risk of the cancer returning (relapse) and generally lower long-term survival rates compared to a good response ^[3][6].

However, many children with a poor histologic response remain disease-free. A poor response does not determine your child’s individual outcome ^[6]. It is just one piece of a larger puzzle. Doctors will interpret this grade alongside other crucial factors, such as:

• Whether the cancer had spread (metastasized) at the time of diagnosis ^[7].
• The location of the primary tumor (e.g., limbs vs. spine or pelvis) ^[7].
• The specific subtype of osteosarcoma ^[8].
• Whether the surgeon achieved clear surgical margins (a border of healthy tissue around the tumor) ^[9]. Clear margins lower the risk of cancer returning at the operation site, though they do not rule out microscopic disease elsewhere.

Why Not Just Add More Chemotherapy Drugs?

A natural question many parents have after learning about a poor response is: “Should we add different chemotherapy drugs to kill the remaining cancer?”

To answer this exact question, researchers conducted a massive international study called the EURAMOS-1 trial. In this study, patients with resectable osteosarcoma who had a poor histologic response to standard MAP chemotherapy (methotrexate, doxorubicin, and cisplatin) were divided into two groups after surgery ^[10]:

1. One group continued with the standard MAP chemotherapy ^[10].
2. The other group received MAP chemotherapy plus two additional chemotherapy agents: ifosfamide and etoposide (a combination called MAPIE) ^[10].

The trial found that routinely adding the extra drugs did not improve event-free survival (the chance of remaining free of cancer) ^[10]. Furthermore, the additional drugs caused significantly more severe side effects (toxicity) ^[10]. Patients receiving the MAPIE combination experienced much higher rates of dangerous drops in white blood cell counts with fever (febrile neutropenia) and other severe complications ^[10].

Because of the EURAMOS-1 findings, routine intensification of chemotherapy with MAPIE is not recommended as a standard approach for poor responders outside of an appropriate clinical trial ^[10]. While many children resume or complete the planned postoperative MAP regimen, your treating team will individualize the plan based on the pathology results, organ function, and potential clinical trial options.

What Happens Next: Surveillance and Next Steps

After surgery and post-operative chemotherapy, your child will enter a period of surveillance. This involves scheduled clinical visits and imaging, particularly chest scans, to monitor for relapse. Relapse is often detected by these scans rather than by symptoms at home. You should always follow the scheduled scan routine and never wait for symptoms to occur before checking in. However, you should still report new or worsening symptoms—such as persistent pain, swelling, reduced function, or breathing difficulty—to your care team promptly.